Cordis Launching Two New Products at EuroPCR Congress

Cordis Continues its History of Innovation With Two New Products: EMPIRA(TM) and RADIALSOURCE(TM)

PARIS, May 16, 2011 - Cordis announced it has obtained CE mark for its EMPIRA(TM)
and EMPIRA(TM) NC RX PTCA* Dilatation Catheters for the treatment of coronary
artery disease. The EMPIRA(TM) systems are designed to enable interventional
cardiologists to open patients' narrowed coronary arteries during angioplasty
and stenting procedures.

The EMPIRA(TM) family of PTCA dilatation catheters
incorporates several design and technology changes that have the potential to
improve crossability and recrossability, allowing a physician to reach even
hard to treat lesions. Both catheters utilise the next generation DURALYN(R)
Flex balloon material which is 50% more flexible than the DURALYN(R) balloon
material used in the current dilatation catheters[1]. EMPIRA(TM) will be made
available in selected sizes to a limited number of centres in Europe during
the summer. A full European commercial launch of EMPIRA(TM) is planned for Q4
2011.

"The EMPIRA(TM) family of PTCA dilatation catheters offers our
most advanced technology designed to treat challenging coronary artery
disease," said Campbell Rogers, MD, Cordis Chief Scientific Officer, Global
Head R&D. "Cordis worked closely with our physician-customers and
incorporated their feedback into the design of these next generation devices.
We believe the unique design of the EMPIRA(TM) and EMPIRA(TM) NC PTCA
Dilatation Catheters will meet physicians' needs and expand the array of high
quality tools that we offer to physicians to treat their patients with
coronary artery disease."

Cordis Radial Solutions - Integrated Solutions for Transradial
Care

Cordis announces the launch in Europe of Radial Solutions, a
complete portfolio for transradial interventions. New to the portfolio is the
Cordis RADIALSOURCE(TM) Transradial Access Kit. RADIALSOURCE(TM) transradial
sheaths are designed to provide cardiologists with atraumatic and smooth
access to the radial artery during diagnostic and interventional procedures.

The RADIALSOURCE(TM) transradial sheath incorporates a new
tapering design in conjunction with a lubricious coating, offering the
benefits of low insertion force with a smooth atraumatic entry, while
enabling stability during procedure and ease of removal. Physicians will be
offered a choice of kit with a bare metal or a polymer-coated guidewire.

Cordis Radial Solutions encompass Cordis' well known guiding
and diagnostic catheters with new specific radial shapes, transradial sheath
introducer, guidewires and professional education training.

"Radial access, with much fewer bleeding complications is
becoming the dominant access site in many countries. To meet this need Cordis
has introduced their 'Radial Solutions portfolio' which includes a
comprehensive range of dedicated radial sheaths and introducer options and
have a haemostasis device on the way. As a keen radial interventionalist it
is great to see Cordis taking such an active interest in radial access" said
Douglas G. Fraser, MB BChir MRCP DM, Interventional Cardiologist, Manchester
Heart Centre, Manchester Royal Infirmary UK.

About Cordis Corporation

For more than 50 years, Cordis Corporation, a Johnson &
Johnson company, has been a worldwide leader in the development and
manufacture of interventional vascular technology. Through the company's
innovation, research and development, Cordis partners with interventional
cardiologists worldwide to treat millions of patients who suffer from
vascular disease.

Reference:

Cordis data on file, 2010/2011.

*Percutaneous transluminal coronary angioplasty

Name: Hans Vanavermaete Director, Communications & Public Affairs (m) +32-478-447-278